HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression - Top-Institutions - MDSpire

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • By

  • Juan Wang

  • Kang Wang

  • Zhenhong Hu

  • Xueting Hu

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Herlev and Gentofte Hospital Research Council
    Herlev and Gentofte Hospital Research Council

    Herlev, Denmark

    Key Differentiators

    • Oncology

  • #3

    Center for Cancer Immune Therapy, Herlev Hospital
    Center for Cancer Immune Therapy, Herlev Hospital

    Herlev, Denmark

    Key Differentiators

    • Oncology

  • #4

    Rutgers Cancer Institute of New Jersey
    Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

    Key Differentiators

    • Oncology

  • #5

    Vanderbilt-Ingram Cancer Center
    Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

    Key Differentiators

    • Oncology

Original Source(s)

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

  • by Juan Wang, Kang Wang, Zhenhong Hu, Xueting Hu

  • May 25, 2026

Related Content

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method